title: Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance.
abstract: Twenty-two consecutive liver allograft recipients, who tested positive for immunoglobulin G (IgG) lymphocytotoxicity were subjected to pretransplantation and posttransplantation immunologic monitoring of anti-donor IgG lymphocytotoxic antibody titers, total hemolytic complement activity (CH100), circulating immune complexes (CIC), and platelet counts in an effort to improve our understanding of the preformed antibody state in clinical hepatic transplantation. Ten contemporaneous liver transplant recipients whose crossmatch results were negative and who experienced severe hepatocellular damage early after transplantation were included as controls. Crossmatch test results were negative 1 day after transplantation and during the 1 month follow-up remained negative in 14 of 22 (64%) sensitized recipients, most of whom had relatively low (< or = 1:16) anti-donor IgG antibody titers before transplantation. After transplantation, this group and the control group experienced no thrombocytopenia, no increase of CIC, and a gradual increase in CH100 activity that reached normal levels within 1 week. A strong negative correlation between prothrombin time (PT) and CH100 activity in these groups of patients suggested that changes in CH100 activity (P < .0005) were tightly linked to liver synthetic function. In contrast, the crossmatch test results remained positive after transplantation in 8 of 22 (36%) sensitized recipients, all of whom had relatively high (> 1:32 to 1024) pretransplantation titers of anti-donor IgG antibodies. After transplantation these patients developed a syndrome that was characterized by decreased CH100 activity and increased CIC compared with pretransplantation levels and refractory thrombocytopenia that was associated with a 50% allograft failure rate because of biopsy-proven humoral and acute (cellular) rejection.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, Pittsburgh Transplant Institute, University of Pittsburgh School of Medicine, PA, USA.
authors.forename: R
authors.initials: R
authors.lastname: Mañez
authors.forename: R H
authors.initials: RH
authors.lastname: Kelly
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Takaya
authors.forename: O
authors.initials: O
authors.lastname: Bronsther
authors.forename: D
authors.initials: D
authors.lastname: Kramer
authors.forename: R J
authors.initials: RJ
authors.lastname: Duquesnoy
authors.forename: Y
authors.initials: Y
authors.lastname: Iwaki
authors.forename: J J
authors.initials: JJ
authors.lastname: Fung
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
mesh_terms: D000328:Adult; D000368:Aged; D000936:Antigen-Antibody Complex / Q000032:analysis; D000961:Antilymphocyte Serum / Q000032:analysis*; D001788:Blood Grouping and Crossmatching; D003165:Complement System Proteins / Q000378:metabolism; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis*; D008099:Liver / Q000378:metabolism; D008111:Liver Function Tests; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011184:Postoperative Period; D011446:Prospective Studies
chemical_list: D000936:Antigen-Antibody Complex; D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D003165:Complement System Proteins